Aligos Therapeutics (NASDAQ:ALGS) Shares Up 5% – Should You Buy?

Aligos Therapeutics, Inc. (NASDAQ:ALGS)’s stock price was up 5% during mid-day trading on Wednesday . The company traded as high as $10.44 and last traded at $10.29. Approximately 49,337 shares traded hands during trading, a decline of 25% from the average daily volume of 65,705 shares. The stock had previously closed at $9.80.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Aligos Therapeutics in a report on Friday, September 12th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, Aligos Therapeutics currently has a consensus rating of “Buy” and an average target price of $50.00.

Aligos Therapeutics Trading Up 5.0%

The business has a fifty day simple moving average of $9.41 and a two-hundred day simple moving average of $7.79. The stock has a market cap of $63.28 million, a PE ratio of -0.52 and a beta of 2.77.

Aligos Therapeutics (NASDAQ:ALGS) last posted its earnings results on Wednesday, August 6th. The company reported ($1.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.35) by $0.82. Aligos Therapeutics had a negative return on equity of 22.41% and a negative net margin of 2,337.24%.The firm had revenue of $0.97 million for the quarter, compared to the consensus estimate of $0.43 million. On average, research analysts predict that Aligos Therapeutics, Inc. will post -10.36 earnings per share for the current year.

Institutional Trading of Aligos Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Adage Capital Partners GP L.L.C. boosted its position in shares of Aligos Therapeutics by 43.1% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 465,000 shares of the company’s stock worth $3,836,000 after purchasing an additional 140,000 shares in the last quarter. Alyeska Investment Group L.P. bought a new stake in shares of Aligos Therapeutics in the 1st quarter worth approximately $3,399,000. Sio Capital Management LLC boosted its position in shares of Aligos Therapeutics by 85.9% in the 2nd quarter. Sio Capital Management LLC now owns 335,937 shares of the company’s stock worth $2,422,000 after purchasing an additional 155,217 shares in the last quarter. Woodline Partners LP bought a new stake in shares of Aligos Therapeutics in the 1st quarter worth approximately $2,602,000. Finally, Heights Capital Management Inc. bought a new stake in shares of Aligos Therapeutics in the 1st quarter worth approximately $1,992,000. 60.43% of the stock is owned by institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).